Blood tests to track mutations in lower-risk MDS
Part of Blood & lymphatic clinical trials.
This study uses repeated blood samples to watch how genetic changes in your blood evolve in lower-risk myelodysplastic syndrome (MDS). It may help doctors understand what mutation changes mean over time for people not on strong cancer-fighting treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MDS that is “very low,” “low,” or “intermediate” risk by IPSS-R
- You are not on cancer-fighting treatment, or you receive only supportive care
- Supportive care can include erythropoietin (a medicine to help with anemia)
- You do NOT have the specific diagnosis “MDS with isolated del(5q)”
- You are not taking disease-modifying therapies such as hypomethylating agents
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This study looks at special stem cells in the blood or bone marrow of people with myelodysplastic syndromes (MDS). It aims to better predict how the disease might progress and help guide treatment decisions.
This study looks at whether healthy lifestyle changes (such as diet and exercise) can help people with low-risk Myelodysplastic Syndrome (MDS), a condition where the bone marrow doesn't produce enough healthy blood cells. It may improve anemia and overall well-being.
This study is looking at how a certain biological pathway (called BMP) affects the progression of blood cancers like MDS and AML. By understanding this, doctors hope to find better ways to predict or treat these conditions.
This trial collects and stores biological samples (like blood or other lab materials) from people with myelodysplastic syndrome, to help researchers learn more about the disease. It may help future diagnosis or treatments, even if it doesn’t directly test a new medicine.
This study follows people with ongoing low blood counts (red cells, white cells, and/or platelets) to better understand their condition when it does not meet criteria for MDS. It may help improve how persistent blood count problems are evaluated over time.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.